-
1
-
-
41349100708
-
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
-
Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111(4):1827–1833.
-
(2008)
Blood
, vol.111
, Issue.4
, pp. 1827-1833
-
-
Goldstone, A.H.1
Richards, S.M.2
Lazarus, H.M.3
-
2
-
-
28444490353
-
Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
-
Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–3767.
-
(2005)
Blood
, vol.106
, Issue.12
, pp. 3760-3767
-
-
Rowe, J.M.1
Buck, G.2
Burnett, A.K.3
-
3
-
-
33846869976
-
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ ECOG 2993 study
-
Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ ECOG 2993 study. Blood. 2007;109(3):944–950.
-
(2007)
Blood
, vol.109
, Issue.3
, pp. 944-950
-
-
Fielding, A.K.1
Richards, S.M.2
Chopra, R.3
-
4
-
-
84924412997
-
Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia
-
Deangelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015; 29(3):526–534.
-
(2015)
Leukemia
, vol.29
, Issue.3
, pp. 526-534
-
-
Deangelo, D.J.1
Stevenson, K.E.2
Dahlberg, S.E.3
-
5
-
-
60949101218
-
Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study
-
Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911–918.
-
(2009)
J Clin Oncol
, vol.27
, Issue.6
, pp. 911-918
-
-
Huguet, F.1
Leguay, T.2
Raffoux, E.3
-
6
-
-
85042937385
-
Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia
-
Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia. 2018;32(3):606–615.
-
(2018)
Leukemia
, vol.32
, Issue.3
, pp. 606-615
-
-
Toft, N.1
Birgens, H.2
Abrahamsson, J.3
-
7
-
-
85030548518
-
Acute lymphoblastic leukemia: A comprehensive review and 2017 update
-
Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.
-
(2017)
Blood Cancer J
, vol.7
, Issue.6
-
-
Terwilliger, T.1
Abdul-Hay, M.2
-
8
-
-
84988449072
-
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
-
Maury S, Chevret S, Thomas X, et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N Engl J Med. 2016;375(11): 1044–1053.
-
(2016)
N Engl J Med
, vol.375
, Issue.11
, pp. 1044-1053
-
-
Maury, S.1
Chevret, S.2
Thomas, X.3
-
9
-
-
84981156388
-
New monoclonal antibodies for the treatment of acute lymphoblastic leukemia
-
Farhadfar N, Litzow MR. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. Leuk Res. 2016;49:13–21.
-
(2016)
Leuk Res
, vol.49
, pp. 13-21
-
-
Farhadfar, N.1
Litzow, M.R.2
-
10
-
-
84885426867
-
Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia
-
Hoelzer D. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. Curr Opin Oncol. 2013;25(6):701–706.
-
(2013)
Curr Opin Oncol
, vol.25
, Issue.6
, pp. 701-706
-
-
Hoelzer, D.1
-
11
-
-
84933505636
-
Monoclonal antibodies in acute lymphoblastic leukemia
-
Jabbour E, O’Brien S, Ravandi F, Kantarjian H. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015;125(26): 4010–4016.
-
(2015)
Blood
, vol.125
, Issue.26
, pp. 4010-4016
-
-
Jabbour, E.1
O’Brien, S.2
Ravandi, F.3
Kantarjian, H.4
-
14
-
-
0030993376
-
CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling
-
Tedder TF, Tuscano J, Sato S, Kehrl JH, Cd KJH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997;15:481–504.
-
(1997)
Annu Rev Immunol
, vol.15
, pp. 481-504
-
-
Tedder, T.F.1
Tuscano, J.2
Sato, S.3
Kehrl, J.H.4
Cd, K.J.H.5
-
15
-
-
79551641737
-
Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia
-
Piccaluga PP, Arpinati M, Candoni A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma. 2011;52(2): 325–327.
-
(2011)
Leuk Lymphoma
, vol.52
, Issue.2
, pp. 325-327
-
-
Piccaluga, P.P.1
Arpinati, M.2
Candoni, A.3
-
16
-
-
10744229449
-
Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
-
Dijoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004; 103(5):1807–1814.
-
(2004)
Blood
, vol.103
, Issue.5
, pp. 1807-1814
-
-
Dijoseph, J.F.1
Armellino, D.C.2
Boghaert, E.R.3
-
17
-
-
0027194197
-
Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics
-
Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993;53(14):3336–3342.
-
(1993)
Cancer Res
, vol.53
, Issue.14
, pp. 3336-3342
-
-
Hinman, L.M.1
Hamann, P.R.2
Wallace, R.3
Menendez, A.T.4
Durr, F.E.5
Upeslacis, J.6
-
18
-
-
84939267428
-
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
-
Pt A
-
Shor B, Gerber HP, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2 Pt A):107–116.
-
(2015)
Mol Immunol
, vol.67
, Issue.2
, pp. 107-116
-
-
Shor, B.1
Gerber, H.P.2
Sapra, P.3
-
19
-
-
84956957250
-
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
-
George B, Kantarjian H, Jabbour E, Jain N. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy. 2016;8(2):135–143.
-
(2016)
Immunotherapy
, vol.8
, Issue.2
, pp. 135-143
-
-
George, B.1
Kantarjian, H.2
Jabbour, E.3
Jain, N.4
-
20
-
-
77951648118
-
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: Results of a phase I study
-
Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085–2093.
-
(2010)
J Clin Oncol
, vol.28
, Issue.12
, pp. 2085-2093
-
-
Advani, A.1
Coiffier, B.2
Czuczman, M.S.3
-
21
-
-
84860243682
-
Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma
-
Ogura M, Hatake K, Ando K, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012;103(5):933–938.
-
(2012)
Cancer Sci
, vol.103
, Issue.5
, pp. 933-938
-
-
Ogura, M.1
Hatake, K.2
Ando, K.3
-
22
-
-
79952095577
-
Modern therapy of acute lymphoblastic leukemia
-
Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532–543.
-
(2011)
J Clin Oncol
, vol.29
, Issue.5
, pp. 532-543
-
-
Bassan, R.1
Hoelzer, D.2
-
23
-
-
79954448903
-
Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (Inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP
-
Dijoseph JF, Dougher MM, Evans DY, Zhou BB, Damle NK. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother Pharmacol. 2011;67(4): 741–749.
-
(2011)
Cancer Chemother Pharmacol
, vol.67
, Issue.4
, pp. 741-749
-
-
Dijoseph, J.F.1
Dougher, M.M.2
Evans, D.Y.3
Zhou, B.B.4
Damle, N.K.5
-
24
-
-
84856710962
-
The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells
-
de Vries JF, Zwaan CM, de Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26(2):255–264.
-
(2012)
Leukemia
, vol.26
, Issue.2
, pp. 255-264
-
-
de Vries, J.F.1
Zwaan, C.M.2
de Bie, M.3
-
25
-
-
35548931579
-
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia
-
Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21(11):2240–2245.
-
(2007)
Leukemia
, vol.21
, Issue.11
, pp. 2240-2245
-
-
Dijoseph, J.F.1
Dougher, M.M.2
Armellino, D.C.3
Evans, D.Y.4
Damle, N.K.5
-
26
-
-
84862786326
-
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study
-
Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012; 13(4):403–411.
-
(2012)
Lancet Oncol
, vol.13
, Issue.4
, pp. 403-411
-
-
Kantarjian, H.1
Thomas, D.2
Jorgensen, J.3
-
27
-
-
84880574025
-
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
-
Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728–2736.
-
(2013)
Cancer
, vol.119
, Issue.15
, pp. 2728-2736
-
-
Kantarjian, H.1
Thomas, D.2
Jorgensen, J.3
-
28
-
-
85029142692
-
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: A phase 1/2 study
-
Deangelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1(15):1167–1180.
-
(2017)
Blood Adv
, vol.1
, Issue.15
, pp. 1167-1180
-
-
Deangelo, D.J.1
Stock, W.2
Stein, A.S.3
-
29
-
-
84984677465
-
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
-
Kantarjian HM, Deangelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med Overseas Ed. 2016;375(8):740–753.
-
(2016)
N Engl J Med Overseas Ed
, vol.375
, Issue.8
, pp. 740-753
-
-
Kantarjian, H.M.1
Deangelo, D.J.2
Stelljes, M.3
-
30
-
-
85041221680
-
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE
-
Jabbour EJ, Deangelo DJ, Stelljes M, et al. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018;124(8):1722–1732.
-
(2018)
Cancer
, vol.124
, Issue.8
, pp. 1722-1732
-
-
Jabbour, E.J.1
Deangelo, D.J.2
Stelljes, M.3
-
31
-
-
85045950102
-
Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia
-
Jabbour E, Ravandi F, Kebriaei P, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia. JAMA Oncol. 2018;4(2):230–234.
-
(2018)
JAMA Oncol
, vol.4
, Issue.2
, pp. 230-234
-
-
Jabbour, E.1
Ravandi, F.2
Kebriaei, P.3
-
32
-
-
77954839504
-
Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
-
Ogura M, Tobinai K, Hatake K, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010;101(8): 1840–1845.
-
(2010)
Cancer Sci
, vol.101
, Issue.8
, pp. 1840-1845
-
-
Ogura, M.1
Tobinai, K.2
Hatake, K.3
-
33
-
-
84860243682
-
Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma
-
Ogura M, Hatake K, Ando K, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012;103(5):933–938.
-
(2012)
Cancer Sci
, vol.103
, Issue.5
, pp. 933-938
-
-
Ogura, M.1
Hatake, K.2
Ando, K.3
-
34
-
-
84875434050
-
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: Results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab
-
Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573–583.
-
(2013)
J Clin Oncol
, vol.31
, Issue.5
, pp. 573-583
-
-
Fayad, L.1
Offner, F.2
Smith, M.R.3
-
35
-
-
85051599508
-
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
-
Dang NH, Ogura M, Castaigne S, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2017;28.
-
(2017)
Br J Haematol
, pp. 28
-
-
Dang, N.H.1
Ogura, M.2
Castaigne, S.3
-
36
-
-
85021846886
-
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: Results from the open-label, randomised, phase 3 INO-VATE study
-
Kantarjian HM, Deangelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017; 4(8):e387–e398.
-
(2017)
Lancet Haematol
, vol.4
, Issue.8
, pp. e387-e398
-
-
Kantarjian, H.M.1
Deangelo, D.J.2
Advani, A.S.3
-
37
-
-
0027478056
-
Veno-occlusive Disease of the Liver and Multio-rgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients
-
Mcdonald GB, et al. Veno-occlusive Disease of the Liver and Multio-rgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients. Ann Intern Med. 1993;118(4):255.
-
(1993)
Ann Intern Med
, vol.118
, Issue.4
, pp. 255
-
-
McDonald, G.B.1
-
38
-
-
0021363719
-
Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors
-
Mcdonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4(1): 116–122.
-
(1984)
Hepatology
, vol.4
, Issue.1
, pp. 116-122
-
-
McDonald, G.B.1
Sharma, P.2
Matthews, D.E.3
Shulman, H.M.4
Thomas, E.D.5
-
39
-
-
0023552434
-
Venoocclusive disease of the liver following bone marrow transplantation
-
Jones RJ, Lee KSK, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987; 44(6):778–783.
-
(1987)
Transplantation
, vol.44
, Issue.6
, pp. 778-783
-
-
Jones, R.J.1
Lee, K.S.K.2
Beschorner, W.E.3
-
40
-
-
79952615903
-
Defi-brotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic Stem Cell Transplantation
-
Palomo M, Diaz-Ricart M, Rovira M, Escolar G, Carreras E. Defi-brotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 2011;17(4):497–506.
-
(2011)
Biology of Blood and Marrow Transplantation
, vol.17
, Issue.4
, pp. 497-506
-
-
Palomo, M.1
Diaz-Ricart, M.2
Rovira, M.3
Escolar, G.4
Carreras, E.5
-
41
-
-
84880700119
-
Defi-brotide: Properties and clinical use of an old/new drug
-
Pescador R, Capuzzi L, Mantovani M, Fulgenzi A, Ferrero ME. Defi-brotide: Properties and clinical use of an old/new drug. Vascul Pharmacol. 2013;59(1–2):1–10.
-
(2013)
Vascul Pharmacol
, vol.59
, pp. 1-2
-
-
Pescador, R.1
Capuzzi, L.2
Mantovani, M.3
Fulgenzi, A.4
Ferrero, M.E.5
-
42
-
-
84963563658
-
Phase 3 trial of defibrot-ide for the treatment of severe veno-occlusive disease and multi-organ failure
-
Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrot-ide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656–1665.
-
(2016)
Blood
, vol.127
, Issue.13
, pp. 1656-1665
-
-
Richardson, P.G.1
Riches, M.L.2
Kernan, N.A.3
-
43
-
-
85040318688
-
Management of important adverse events associated with inotuzumab ozogamicin: Expert panel review
-
Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53(4):449–456.
-
(2018)
Bone Marrow Transplant
, vol.53
, Issue.4
, pp. 449-456
-
-
Kebriaei, P.1
Cutler, C.2
de Lima, M.3
-
44
-
-
85014771892
-
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
-
Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med Overseas Ed. 2017;376(9):836–847.
-
(2017)
N Engl J Med Overseas Ed
, vol.376
, Issue.9
, pp. 836-847
-
-
Kantarjian, H.1
Stein, A.2
Gökbuget, N.3
-
45
-
-
85041377767
-
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
-
Park JH, Rivière I, Gonen M, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med Overseas Ed. 2018;378(5):449–459.
-
(2018)
N Engl J Med Overseas Ed
, vol.378
, Issue.5
, pp. 449-459
-
-
Park, J.H.1
Rivière, I.2
Gonen, M.3
-
46
-
-
85032490661
-
FDA approves first CAR T therapy
-
Mullard A. FDA approves first CAR T therapy. Nat Rev Drug Discov. 2017;16(10):669.
-
(2017)
Nat Rev Drug Discov
, vol.16
, Issue.10
, pp. 669
-
-
Mullard, A.1
-
47
-
-
85057810889
-
-
August 17, Accessed July 7, 2018
-
Reuters Staff. FDA approves Pfizer’s drug for rare blood cancer; 2017, August 17. Available from: https://in.reuters.com/article/us-pfizer-fda-leukemia-idINKCN1AX2A0. Accessed July 7, 2018.
-
(2017)
FDA Approves Pfizer’s Drug for Rare Blood Cancer
-
-
|